ArsenalBio Stock

ArsenalBio is a programmable cell therapy company.

Sign up today and learn more about ArsenalBio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About ArsenalBio Stock

ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.

Funding History

October 2019$85.0M


Chief Technology Officer

Tarjei Mikkelsen

Chief Scientific Officer

Jane Grogan

CEO, President & Director

Ken Drazan


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: